Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Shares Outstanding data on record, last reported at $29.2 million in Q3 2025.

  • For Q3 2025, Shares Outstanding changed N/A year-over-year to $29.2 million; the TTM value through Sep 2025 reached $29.2 million, changed N/A, while the annual FY2024 figure was $6.7 million, 57.69% down from the prior year.
  • Shares Outstanding reached $22.8 million in Q3 2025 per CTNM's latest filing, down from $25.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $25.9 million in Q2 2025 and bottomed at $2.3 million in Q2 2023.
  • Average Shares Outstanding over 3 years is $14.0 million, with a median of $13.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: skyrocketed 600.06% in 2024, then plummeted 57.69% in 2025.
  • A 3-year view of Shares Outstanding shows it stood at $2.3 million in 2023, then soared by 186.4% to $6.7 million in 2024, then skyrocketed by 333.67% to $29.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $29.2 million in Q3 2025, $25.9 million in Q2 2025, and $6.7 million in Q1 2025.